

ReNerve

ASX:RNV

Transforming Nerve Repair Through Science

Quarterly update

ReNerve Company update | August 2025

Important Notice & Disclaimer

Nature of Document: This presentation has been prepared and issued by ReNerve Ltd (Company) to provide general information about the Company. The information in this document is in summary form and should not be relied upon as a complete and accurate representation of any matters that a reader should consider in evaluating the Company. While management has taken every effort to ensure the accuracy of the material in this presentation, the Company have not verified the accuracy or completeness of the material contained in this presentation.

Not an offer: this presentation should not be distributed, transmitted, or viewed by any person in any jurisdiction where the distribution, transmission or viewing of this document would be unlawful under the securities or other laws of that or any other jurisdiction.

Not financial product advice: You should not act and should refrain from acting in reliance on this presentation. Nothing contained in this presentation constitutes investment, legal, tax or other advice. This presentation does not take into account the individual investment objectives, financial situation and particular needs of potential investors. Before making a decision to invest in the Company at any time, you should conduct, with the assistance of your broker or other financial or professional adviser, your own investigation in light of your particular investment needs, objectives and financial circumstances and perform your own analysis of the Company before making any investment decision.

Forward looking statements: This presentation contains forward-looking information about the Company and its operations. In certain cases, forward-looking information may be identified by such terms as "anticipates", "believes", "should", "could", "estimates", "target", "likely", "plan", "expects", "may", "intend", "shall", "will", or "would". These statements are based on information currently available to the Company and the Company provides no assurance that actual results will meet management's expectations. Forward-looking statements are subject to risk factors associated with the Company's business, many of which are beyond the control of the Company. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a variety of variables and changes in underlying assumptions which could cause actual results or trends to differ materially from those expressed or implied in such statements. There can be no assurance that actual outcomes will not differ materially from these statements.

Disclaimer: No representation or warranty, express or implied, is made by the Company that the material contained in this presentation will be achieved or proved correct. Except for statutory liability which cannot be excluded, the Company, its directors, officers, and employees expressly disclaim any responsibility for the accuracy, fairness, sufficiency or completeness of the material contained in this presentation and excludes all liability whatsoever (including in negligence) for any loss or damage which may be suffered by any person as a consequence of any information in this presentation or any effort or omission therefrom. The Company will not update or keep current the information contained in this presentation or to correct any inaccuracy or omission which may become apparent, or to furnish any person with any further information. Any opinions expressed in the presentation are subject to change without notice. An offer of Shares in ReNerve Ltd (ABN 23 614 848 216) is being made in or accompanied by a prospectus dated at a date to be confirmed. Anyone who wants to acquire Shares pursuant to the offer will need to complete the application form that accompanies the prospectus. A person should consider and rely only on the prospectus in deciding whether to invest. A copy of the prospectus is available by contacting the Company or by downloading from the Company's website (www.renerve.com.au).

Speculative nature of investment: Any potential investor should be aware that subscribing for Shares involves various risks. The Shares to be issued pursuant to the Prospectus lodged with ASIC by ReNerve Ltd carry no guarantee with respect to the payment of dividends, returns of capital or the market value of those Shares. An investment in Shares of the Company should therefore be considered very speculative.

Executive Summary



Development of Novel Nerve Repair & Regeneration Products

ReNerve is developing a portfolio of products for the nerve repair and regeneration markets, with clearly defined commercial demand.



Expanding Product Portfolio

4 product ranges expected on market by year end, with more in development and research.



Strong Sales & Distribution Presence

ReNerve has established logistics, warehouse and invoicing infrastructure with a strong focus on building a sales distribution network for all products.




Global Expansion & Commercialisation

Successful ongoing expansion within the first year of ASX listing into major surgical markets throughout Asia, The Middle East, and The Americas.



Clinical & Professional Validation

Improved patient outcomes for post-surgical measures of pain and surgery satisfaction, as well as proven ease of use for surgeons.




ReNerve Target Markets


MarketWide Research – Dermal and Amniotic tissue
market report 2025-2032, Published 2025.

Global Nerve Repair Biomaterials Market Research
Report (2020 – 2031)

Global Nerve Repair Biomaterial Market



Dermal & Amniotic Tissue Sales market in USD\$M



ReNerve's Nerve Opportunity

ReNerve Nerve Cuff



ReNerve Nerve Conduit



ReNerve Nerve Guide Matrix



ReNerve Bionic Nerve



Product	<ul style="list-style-type: none"> Used on damaged or transected nerves with no gaps or gap closure 	<ul style="list-style-type: none"> Improved Nerve Cuff developed from scCO2 tissue, offering better product profile 	<ul style="list-style-type: none"> An 'off-the-shelf', ready to use nerve graft replacement with internal guidance infrastructure 	<ul style="list-style-type: none"> An 'off-the-shelf', continuous nerve replacement, in a ready to use nerve structure
Procedure Use	<ul style="list-style-type: none"> End to end suturing covered with a wrap/cuff Protective cuff for grafts 	<ul style="list-style-type: none"> Protecting injured nerve repairs 	<ul style="list-style-type: none"> Replaces damaged nerve section instead of using donor or harvested tissue 	<ul style="list-style-type: none"> The Bionic Nerve is a nerve guide matrix with ionic polymers designed to replace injured and damaged nerves for lengths from 1cm to 20cm
Application	<ul style="list-style-type: none"> Trauma Breast reconstruction Orthopaedics Oral & maxillofacial surgery 	<ul style="list-style-type: none"> Trauma Breast reconstruction Orthopaedics Foot and ankle 	<ul style="list-style-type: none"> Trauma Breast reconstruction Orthopaedics Hand & wrist 	<ul style="list-style-type: none"> Trauma Craniotomy Spinal cord injury Spinal cord surgery
Benefit	<ul style="list-style-type: none"> Bio-absorbed removing need for additional surgery Pliable and conforms 	<ul style="list-style-type: none"> Improved product profile to Nerve Cuff Stronger patient reimbursement 	<ul style="list-style-type: none"> Can be cut to ideal length Off-the-shelf, reducing logistics issues Simple to use and cost effective 	<ul style="list-style-type: none"> Enable production of nerves of bespoke dimension
FDA Status	Approved	Targeting Q4 CY25 filing	Targeting Q2 CY27 filing	Targeting Q3 CY28 filing
TAM (USD)	<div> <div>\$314m</div> <div>\$975m</div> <div>2024</div> <div>2030</div> </div>	<div> <div>\$1015m</div> <div>\$3219m</div> <div>2024</div> <div>2030</div> </div>	<div> <div>\$635m</div> <div>\$1991m</div> <div>2024</div> <div>2030</div> </div>	<div> <div>>\$400m</div> <div>2023</div> </div>

Company Quarterly Highlights

Sales Highlights

- Year on year sales up 53%
- Closing cash of \$4.75M
- Revenue rose by 25% for the quarter
- Costs in line with prospectus forecasted spend

ReNerve Key Quarterly activities

New product ranges to market

- Partnership with Berkeley Biologics for two main product ranges
- Products already approved
- Complement existing target markets
- Aiming to drive greater revenue growth
- \$2Bn+ target market

Partnership to enter the Indian market

- Important nerve repair market
- In the process of seeking market approval
- Major conference scheduled for Sept '25

Approval in Bahrain

- Approval and first product shipment

Distribution Network



Expanded Distribution Channels

Robust portfolio

- Expanded to 21 distributors across the US
- Distributors selling the ReNerve product ranges
- Will include additional products as they come to market

Focus surgical areas Subspecialties

- Hand (upper extremity)
- Breast
- Lower Extremity (M.D.)
- Podiatric Medicine (DPM)
- Plastics Reconstruction
- Head & Neck
- Spine

US based sales support

- Local personnel supporting these distributors
- Focus on approvals and sales



The Berkeley – ReNerve Product Ranges

Why take on these products?

1| Surgeons using NervAlign products routinely use dermal and amniotic membranes in nerve repair cases

2| They also use dermal and amniotic membranes in cases where a nerve repair is not required

3| Taking on these products expands ReNerve's revenue opportunity

4| Suitable for the same sales and distribution channel already established

5| Similar mechanism of action to Nerve Repair portfolio – a matrix protects healing tissue, enabling controlled reconstruction while minimising scarring

6| Already cleared for sale in US

Benefits of Amniotic Product Range

- Used in orthopaedic, plastic and general surgery – especially for chronic wounds and wound closure
- Enables rapid, non-pathologic healing and remodelling of surgical and reconstructive wounds
- Acts as a natural barrier to protect from external environment
- Provide a reservoir of growth factors and cytokines that can help to kick-start healing
- Processed using a proprietary method that improves levels of growth factors, supporting cell attachment and re-epithelialization
- 'High sterility' assurance level (gold standard of 10^{-6}) without compromising natural structure
- Room temperature storage

AMNIOLITE

AMNIODUO

PLACENTAL

Deep-Layer Dermal Product Range

- Used in orthopaedic, plastic and general surgery
- Provides a scaffold for cell infiltration and organised healing
- Scaffold is made from natural bioactive components (collagen, elastin, glycosaminoglycans)
- Unlike competitor products, the deep-layer dermal products are produced using a method that removes the basement membrane layer
- The basement membrane slows down cell penetration and tissue regeneration
- Basement membrane removed to promote a faster healing process
- Pre-hydrated, pliable and flexible to support precise placement
- High sterility assurance level (gold standard of 10^{-6}) without compromising natural structure
- Room temperature storage

DERMAL

Key Dermal Product Benefits



DESIGNED AND PROCESSED TO PRESERVE THE NATURAL MATRIX AS CLOSELY AS POSSIBLE TO UNPROCESSED DERMIS FOR OPTIMAL TISSUE REPAIR AND REGENERATION.




CLOSEST TO NATURAL DERMAL TISSUE, COMPARED TO OTHER DERMAL PRODUCTS¹.




ACHIEVES HIGH STERILITY-ASSURANCE LEVELS, WHILE MAINTAINING A STRUCTURALLY-INTACT MATRIX THAT RETAINS SIMILAR COLLAGEN INTEGRITY, MECHANICAL STRENGTH, AND BIOACTIVE COMPONENTS AS THE NATURAL DERMIS.

Unprocessed
Dermal Tissue



New ReNerve
Dermal Product



Natural Dermal Integrity is Preserved

1) Data on file

Company value drivers for H2 CY25



Continued Distributor Engagement

3 new products ranges into the US market this CY

- Dermal and amniotic products to market this quarter
- First conduit product by year end
- Provides sales teams a range of 4 product by year end, expected to aide sales of NervAlign™ nerve cuff

Working with distributors for additional approvals

Increase product related content creation

- Support product awareness and benefits

Direct ReNerve sales – ReNerve team to 'hold the hands' of distributors for new products and initial sales

Near Term Milestones – 2025

1H 2025

27 February 2025

Partnership Signed for Mexico Market

7 March 2025

R&D Tax Incentive Refund Received

11 March 2025

Thailand Approval & First Hong Kong Sale

28 March 2025

Clinical Study Results Presented

10 April 2025

Partnership for Indian Market Announced

29 April 2025

Q3 FY25 Results: Revenue Growth & Clinical Validation

2H 2025

NervAlign® Nerve Conduit into Market
(Q4 2025/Q1 2026)

Initial sales of the dermal and
amniotic product ranges

Initial Clinical Cases for the
Nerve Conduit

Starting GMP manufacturing runs
of the Nerve Guide Matrix

NervAlign® Nerve Cuff Approvals in
New Countries & Territories

Near Term

Progression of the Nerve
Guide Matrix to Stage 3
of Development

H2 2025 (Estimated) –
India: Regulatory
Approval Pathway
Initiated

First clinical cases using
the nerve guide matrix

NervAlign® Nerve Cuff
filing for European
approval

Investment Highlights



In Market Product

Nerve Cuff transitioned from R&D to commercial sales post FDA market clearance, achieving strong initial product margins.




Immediate Market Need

Product offering promotes nerve injury recovery and regrowth leading to faster patient recovery and better outcomes.



Growing Market

Nerve repair biomaterials and related markets are forecast to grow by >17% pa, estimated to be worth **>US\$6.19Bn by 2031.**



Diverse Product Portfolio

Four product ranges in market by year end, all of which are already developed. Additional products currently under development.



Growing Distribution

Continuing to build sales representation with a targeted-direct sales approach.



Board & Management

Highly accomplished executive team with a proven track record in the development & commercialisation of medical opportunities.

ReNerve

ASX:RNV

Contact

ReNerve Limited

☎ +61 (03) 9482 3940

✉ info@renerve.com.au

📍 Level 10/99 Queen St, Melbourne, Victoria 3000 Australia

